The podcast episodes explore the high costs and affordability challenges associated with the new weight loss drugs Ozempic and Wegovy, developed by Novo Nordisk and Eli Lilly. Episode 1 chronicles the scientific journey and unexpected rise to blockbuster status of these drugs, driven largely by off-label prescriptions for weight loss, while also delving into the personal experiences and societal impacts of the high costs.

Episode 2 further examines the various alternatives patients are pursuing to access these medications, such as compounded versions, cross-border purchases, and unregulated online sources, due to the lack of insurance coverage. The episodes also discuss efforts to increase affordability and expand insurance coverage for these weight loss treatments.